Technology – HedgeChatter

These Biotech Stocks to Buy Profit from Today's "Miracle Cures"

When researching the best biotech stocks to buy, investors often look for companies that will cure terrible, chronic diseases.Until recently, these biotech stocks have been elusive.”Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything,” Money Morning‘s Biotech Investing Specialist Ernie Tremblay said. “It treats. It manages. It postpones the inevitable. But return […]

December 4, 2014 ByKyle Anderson biotech-stocks, field, genetic, modern, organ, personalized, rejuvenation, science, tremblay Comments Off read more

Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm …

Mergers and acquisitions show no signs of slowing down in the biotech sector with a $3.5 billion acquisition agreement being announced. Meanwhile, Biogen (BIIB – Analyst Report) is advancing towards developing a treatment for Alzheimer’s disease.Recap of the Week’s Most Important Stories1. Biogen is set to move its experimental Alzheimer’s disease treatment, BIIB037, into late-stage testing based on promising interim […]

December 3, 2014 ByArpita Dutt biib, biogen, fda, investment, japan, king, major, nasdaq, national, otsuka, report, soliris Comments Off read more

This Biotech Stock Winner Has Wall Street Fooled – Money Morning

Michael A. RobinsonToday I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped – making this is yet another stock that sells off after a slight miss, a […]

December 2, 2014 ByMichael A. Robinson bailout, biotech, company, compound, editor, gilead, michael, missing, nasdaq, sovaldi Comments Off read more

Horrendous Stock Performance Of RedChip Nation Healthcare And …

SummaryDoing due diligence on a small portion of the mosaic theory related to Inovio and other biotechs led me to doing a small initial study on RedChip.
While RedChip has Inovio listed prominently in multiple areas on its website and has recently Tweeted about it, Inovio is not a client and has never paid RedChip.
Biotech and healthcare stocks listed as RedChip […]

December 1, 2014 BySeekingAlpha.com alpha, biotech, company, healthcare, inovio, nasdaq, performance, seeking, seeking-alpha, stock, therapeutics Comments Off read more

Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV …

Once again, deals and collaborations made news in the biotech sector with BioMarin (BMRN – Analyst Report) announcing its intention to acquire Prosensa (RNA – Snapshot Report) and Five Prime Therapeutics (FPRX – Snapshot Report) signing a second immuno-oncology focused deal with Bristol-Myers Squibb.Meanwhile, AbbVie (ABBV – Analyst Report) continues to progress with its hepatitis C virus (HCV) treatment with […]

November 26, 2014 ByZacks Equity Research biogen, bristol, cancer, gene, hcv, myers, nasdaq, RNA, tecfidera Comments Off read more

Abbott Laboratories (ABT), AbbVie Inc (ABBV): Biotech Stocks Set …

William Patalon III: When I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.But it was a management professor who clued me in to some of the best ways to “look past the numbers” and understand what really makes a big company tick.The professor, Janet C. Barnard, retired a few […]

November 21, 2014 ByDavid Bettencourt baltimore, barnard, black, briefing, institute, king, mba, prof-barnard, professor, tufts Comments Off read more

Two Biotech Stocks Set to Double on One Powerful Catalyst :: The …

Two Biotech Stocks Set to Double on One Powerful CatalystCompanies / BioTechNov 21, 2014 – 02:46 PM GMTBy: Money_MorningWilliam Patalon writes: When I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.But it was a management professor who clued me in to some of the best ways to “look […]

November 21, 2014 Byunknown abbott-vascular, calico, money, money-morning, morning, pharma, president, prof-barnard, street, tufts, valley, vascular Comments Off read more

Two Biotech Stocks Set to Double on One Powerful Catalyst

William Patalon IIIWhen I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.But it was a management professor who clued me in to some of the best ways to “look past the numbers” and understand what really makes a big company tick.The professor, Janet C. Barnard, retired a few […]

November 21, 2014 ByWilliam Patalon III baltimore, barnard, briefing, editor, innovation, institute, private-briefing, study, tufts, william Comments Off read more

This Biotech Stock Is Ready To Run: Celldex Therapeutics, Inc …

Biotech stocks surged nicely Tuesday with the iShares Biotechnology ETF rallying more than 2 percent.For the most part, biotech stocks have performed very well over the last month and even the last year.That performance can be seen quite well with names such as Gilead Sciences, Illumina and Vertex Pharmaceuticals all having hit new highs within the last 30 days.However, not […]

November 19, 2014 ByChristian Tharp CMT benzinga, biotechnology, CLDX, health, ishares, market, nasdaq, over-the-last, pharmaceuticals, therapeutics Comments Off read more

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's …

Geron Corporation (GERN – Analyst Report) was in the spotlight last week with the company striking a collaboration deal with Johnson & Johnson for its sole pipeline candidate, imetelstat. Meanwhile, companies like Gilead (GILD – Analyst Report) and Regeneron (REGN – Analyst Report) remained in the news thanks to regulatory updates.Recap of the Week’s Most Important Stories1. Geron, which had […]

November 19, 2014 ByArpita Dutt american, association, biotechnology, company, corporation, fda, GILD, gilead, johnson, king, regeneron, regn Comments Off read more